SS-31 (Elamipretide)

Longevity & mitochondriaFDA-approved (Barth syndrome, 2025)

Also known as: Forzinity

A mitochondria-targeting peptide. Approved for Barth syndrome, a rare mitochondrial disease.

Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.

How it works

Binds cardiolipin in the inner mitochondrial membrane, stabilizing energy production and reducing oxidative stress.

Evidence by goal

GoalGradeWhat the grade means
Longevity & energyBHuman trials (smaller, mixed, or approved outside the US)
Muscle & growth hormoneBHuman trials (smaller, mixed, or approved outside the US)
Heart & circulationCLimited human data, case series or practitioner reports

At a glance

Route
Subcutaneous daily
Half-life
About 4 hours

Reported dosing

40 mg SC daily (trial and label dose). Practitioner wellness use often lower.

Timing: Once daily.

Cycle: Continuous for disease; 4 to 8 week courses in wellness use.

From approved labels where they exist, otherwise from published trials and practitioner reports.

Side effects

  • Injection-site reactions (very common)
  • Headache, dizziness

Who should avoid it

  • Pregnancy

Often combined with

With MOTS-c in mitochondrial protocols.

Key findings

Accelerated FDA approval in 2025 for Barth syndrome. A larger trial in mitochondrial myopathy missed its main goal.

2026 update

Approved only for Barth syndrome; anti-aging use is unproven.

Where it is legal (Oct 2026)

USPrescription
CanadaNot approved
MexicoNot approved
EUNot approved

Sources

Open SS-31 (Elamipretide) in the Peptide Guide Compare all peptides by goal

Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.

Natoorales and e4life.io (Mexico residency and immigration help) are sister businesses founded by Ian Kain.

Scroll to Top